These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31652166)

  • 1. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
    J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
    Meade N; Shi L; Meehan SR; Weiss C; Ismail Z
    J Psychopharmacol; 2020 Aug; 34(8):829-838. PubMed ID: 32648810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia:
    Marder SR; Meehan SR; Weiss C; Chen D; Hobart M; Hefting N
    Schizophr Bull Open; 2021 Jan; 2(1):sgab014. PubMed ID: 34901863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia.
    Allen MH; Citrome L; Pikalov A; Hsu J; Loebel A
    Gen Hosp Psychiatry; 2017 Jul; 47():75-82. PubMed ID: 28807142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Correll CU; He Y; Therrien F; MacKenzie E; Meehan SR; Weiss C; Hefting N; Hobart M
    J Clin Psychiatry; 2022 Mar; 83(2):. PubMed ID: 35235720
    [No Abstract]   [Full Text] [Related]  

  • 9. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.
    Citrome L; Komaroff M; Starling B; Byreddy S; Terahara T; Hasebe M
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35687858
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder.
    Citrome L; Li C; Yu J; Kramer K; Nguyen HB
    J Affect Disord; 2024 Aug; 358():353-360. PubMed ID: 38657773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    Marder SR; West B; Lau GS; Pultz JA; Pikalov A; Marcus RN; Gutierrez-Esteinou R; Crandall DT
    J Clin Psychiatry; 2007 May; 68(5):662-8. PubMed ID: 17503974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
    Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
    J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
    Newcomer JW; Eriksson H; Zhang P; Weiller E; Weiss C
    Curr Med Res Opin; 2018 Dec; 34(12):2197-2205. PubMed ID: 29985680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    McIntyre RS; Weiller E; Zhang P; Weiss C
    J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.